FAQs
Why do you load doxorubicin when it is an obsolete drug?
Doxorubicin is the most commonly used active agent for treating this patient group. Delivering established molecules with known efficacy in novel delivery systems can substantially benefit patients as shown by the PRECISION I 6-month data.
- Tumour response rate was 78% at 6 months vs 35%
- Tumour response rate was 87% at 6 months at the highest 150mg dose
- Complications rate was 7.5% vs 27.5%
In this section
Disclaimer
The products may not be available for sale, may not be registered, approved or cleared for use as claimed, in all countries where Biocompatibles is represented.